Mobile

A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other P...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-000458-57

A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other Proton Pump Inhibitor (PPI), after initial treatment failure, in ordinary clinical practice during 4 weeks

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to assess how PPI treated GERD-patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation of esomeprazole 40 mg compared to continued pre-study PPI treatment.

Critère d'inclusion

  • Gastroesophageal reflux disease with heartburn as predominant symptom. Treatment failure (defined as 4 days with mild symptoms or 2 days with moderate to severe symptoms during the past 7 days) with previous Proton Pump Inhibitor

Liens